Galaxy Bio, Inc. is a specialty drug developer based in South Brunswick Twp, NJ. They specialize in developing novel dosage forms and proprietary drug delivery systems using their captive Bio-D3, Bio-FX, Bio-CR, Bio-NN, and Bio-MM Drug Delivery System (DDS) technologies. Their products cover a wide range of therapeutic areas including oncology, pain management, central nervous system disorders, smoking cessation, urology, metabolic and cardiovascular diseases, respiratory and allergy conditions, anti-infectives, and motion sickness.
With a global presence, Galaxy Bio focuses on out-licensing their innovative products for various medical needs. Their technology platforms, such as Bio-D3 for transdermal delivery, Bio-FX for orally dissolving films, Bio-CR for oral controlled-release, Bio-NN for nanoparticle controlled-release injectables, and Bio-MM for extended cancer treatments, demonstrate their commitment to advancing drug delivery systems for improved patient outcomes.
Generated from the website